Development of an ultra-sensitive Simoa assay to enable GDF11 detection: a comparison across bioanalytical platforms
Abstract
Background: Four bioanalytical platforms were evaluated to optimize sensitivity and enable detection of recombinant human GDF11 in biological matrices; ELISA, Meso Scale Discovery, Gyrolab xP Workstation and Simoa HD-1. Results & methodology: After completion of custom assay development, the single-molecule ELISA (Simoa) achieved the greatest sensitivity with a lower limit of quantitation of 0.1 ng/ml, an improvement of 100-fold over the next sensitive platform (MSD). Discussion & conclusion: This improvement was essential to enable detection of GDF11 in biological samples, and without the technology the sensitivity achieved on the other platforms would not have been sufficient. Other factors such as ease of use, cost, assay time and automation capability can also be considered when developing custom immunoassays, based on the requirements of the bioanalyst.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 Next generation ligand binding assays-review of emerging technologies’ capabilities to enhance throughput and multiplexing. AAPS J. 16(6), 1175–1184 (2014). • Highlights multiple platforms for ultrasensitive detection of proteins. This review helped guide our decision to invest in the Simoa HD-1 as opposed to other platforms.
- 2 Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153(4), 828–839 (2013). •• Highlights the original thought that recombinant GDF11 therapy can have beneficial cardiac effects in aged mice; however, GDF11 protein is ‘quantitated’ using a western blot, which is only a qualitative assessment. This highlighted the need for a custom assay to accurately measure protein concentration, which did not exist yet.
- 3 . Reduced circulating GDF11 Is unlikely responsible for age-dependent changes in mouse heart, muscle, and brain. Endocrinology 156(11), 3885–3888 (2015).
- 4 GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 22(1), 164–174 (2015). •• Highlights the fact that reagents used in several other papers (SOMAmers, various antibodies) were nonspecific and also detected GDF8. An MSD assay was established with the same reagents (R&D Systems) but they report higher sensitivity; however no standard curve, QC or assay qualification was shown, so there was some doubt with reported results and LLOQ.
- 5 GDF11 does not rescue aging-related pathological hypertrophy. Circ. Res. 117(11), 926–932 (2015). •• Puts the original Loffredo et al. GDF11 publication into doubt, and also shows our Simoa assay enabled the detection and quantitation of GDF11 dosed in mouse at 0.1 mg/kg IP daily, which the previous paper could not show.
- 6 . Application of the Gyrolab platform to ligand-binding assays: a user's perspective. Bioanalysis 2(10), 1711–1715 (2010).
- 7 Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28(6), 595–599 (2010).
- 8 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis 7(24), 3107–3124 (2015).
- 9 US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry, Bioanalytical Method Validation. (2013). www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
- 10 A fully-automated, six-plex single molecule immunoassay for measuring cytokines in blood. J. Immunol. Methods 424, 20–27 (2015). • Highlights the Simoa technology and the theory behind how the assay works, and how increased sensitivity is achieved.
